A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine

What this Trial Is About

This research focuses on chronic inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and interstitial lung diseases (ILD). These conditions involve inflammation and changes in lung structure with a wide range of symptoms and features. The study aims to analyze various characteristics including clinical, biological, and microbiological traits, as well as respiratory exposures and mechanisms related to airway inflammation, to better understand these diseases beyond their initial diagnosis. The study is a prospective cohort conducted at the University Hospital of Reims, France, including adults aged 18 and older diagnosed with the listed respiratory diseases or healthy volunteers as controls. Participants will be followed over a 10-year period with data collected at inclusion and follow-up visits, while controls will only provide data at inclusion. No specific treatments are given as part of the study; care continues as usual. Throughout the study, information such as demographics, disease history, lung function tests, CT scans, and respiratory sample analyses will be collected and stored in an anonymous database. Researchers will use statistical and machine learning methods to identify patient groups with similar disease patterns and predict disease progression and treatment responses. The study is planned to start in September 2025 with a recruitment period lasting five years and follow-up for a decade thereafter.

A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine